FDA approves combination antibiotic for difficult-to-treat infections
The FDA approved the monobactam/beta-lactamase inhibitor combination for use in combination with metronidazole to treat patients who have limited or no treatment options for cIAIs caused by gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
A breakthrough moment: McMaster researchers discover new class of antibiotics
A team led by renowned researcher Gerry Wright has identified a strong candidate to challenge even some of the most drug-resistant bacteria on the planet: a new class of antibiotics called lariocidin.
mRNA vaccines modified to include cytokine IL-12 enhance T cell response
The strong antibody responses generated by vaccines provide an important first round of defense, but "you always want to have a backup plan," says Biomedical Graduate Studies Ph.D. student Emily A. Aunins, considering viruses mutate to evade antibody responses that become widespread in a population.
FDA approves powerful HIV prevention drug: What to know about Yeztugo
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.
U.S. FDA approves twice yearly shot to prevent HIV transmission
U.S. FDA approves twice yearly shot to prevent HIV transmission
